Tenax Therapeutics, Inc. (NASDAQ:TENX) is now up 17.42% compared to a 12-month low of $0.31. We have seen the price to move -5.38% lower and get settled at $0.36 on 12/06/2017. At recent session, it appeared stuck in a range of $0.364 to $0.3966. This company shares are 594.44% off its target price of $2.5 and the current market capitalization stands at $10.74M. The recent change has given its price a -12.19% deficit over SMA 50 and -86.26% deficit over its 52-week high. The stock witnessed -17.54% declines, 7.09% gains and -29.38% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TENX’s volatility during a week at 8.22% and during a month it has been found around 7.84%.Tenax Therapeutics, Inc. (TENX) Top Holders
Institutional investors currently hold around $1 million or 12.9% in TENX stock. Look at its top three institutional owners. Financial Advisory Service, Inc. owns $497 thousand in Tenax Therapeutics, Inc., which represents roughly 4.63% of the company’s market cap and approximately 49.7% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 535,763 shares of the stock are valued at $206 thousand. The third largest holder is Baker Bros. Advisors Lp, which currently holds $134 thousand worth of this stock and that ownership represents nearly 1.25% of its market capitalization.Tenax Therapeutics, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 9 institutional holders increased their position in Tenax Therapeutics, Inc. (NASDAQ:TENX) by some 1,593,664 shares, 9 decreased positions by 545,317 and 13 held positions by 760,378. That puts total institutional holdings at 2,899,359 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 1,313,432 shares while 5 institutional investors sold out their entire positions totaling 45,733 shares.Tenax Therapeutics, Inc. (NASDAQ:TENX) Insider Trades
Multiple company employees have indulged in significant insider trading. Tenax Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Blanck Ronald R has sold 12,950 shares of Tenax Therapeutics, Inc. (TENX) in trading session dated Nov. 14, 2017. These shares are worth $5,051 and were traded at $0.39 each. The SEC filing shows that Proehl Gerald T performed a purchase of 29,882 shares. The Director added these shares by way of transaction on Nov. 23, 2016. The company’s shares were assimilated at $1.67 per share worth to an investment of some $49,903 on account of Proehl Gerald T.
Director, Mitchum James P., purchased 19,000 common shares of Tenax Therapeutics, Inc. (TENX) in the open market. In a transaction dated Feb. 03, 2016, the shares were bought at an average price of $2.66, giving away a sum of $50,540. After this purchase, 19,000 common shares of TENX are directly owned by the insider, with total stake valued at $6,840.
In the transaction dated Nov. 19, 2015, the great number of shares acquired came courtesy the Director; Blanck Ronald R added a total of 1,900 shares at an average price of $3.2, amounting to approximately $6,080. The insider now directly owns 14,799 shares worth $5,328.Tenax Therapeutics, Inc. (TENX) Analyst Guide
Not many analysts have released their opinion on Tenax Therapeutics, Inc. (NASDAQ:TENX), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.